Home > Studies > REDEFINE 3

REDEFINE 3 is looking at a study medicine to assess how effective it is for reducing cardiovascular events, such as heart attack and strokes, in people living with obesity.

We are doing this study to see if the medicine, being developed to treat obesity, is effective at reducing cardiovascular events in people living with obesity who also have cardiovascular disease. The study will also include some people with type 2 diabetes and/or chronic kidney disease.

The term cardiovascular disease is used to describe a group of conditions that affect your heart and blood vessels. These conditions include myocardial infarction (also known as heart attack), stroke, and peripheral arterial disease (also known as poor circulation).

Obesity is when your body stores too much fat. People living with obesity are more likely to have cardiovascular conditions and get other diseases such as type 2 diabetes.

Taking part in this clinical study may improve future treatment options for people living with both obesity and cardiovascular disease.

You may be able to take part if:

  • You have had a stroke, a heart attack (myocardial infarction), or have poor circulation (peripheral arterial disease, or PAD)
  • You are 55 years of age or older
  • You are living with obesity (BMI over 30)
  • You are able to attend regular clinic visits (ranging from every 4-12 weeks depending on the stage of the study) and receive phone phone calls over a period of 3 years.

This study is funded and sponsored by Novo Nordisk.

When you sign up to Research+Me, you may not be contacted immediately. By signing up to the registry, you will find out about any current or future studies that you may be able to take part in.